Kim HK - Search Results

1

A multi-center, late phase II clinical trial of Genexol (paclitaxel) and cisplatin for patients with advanced gastric cancer.

Park SR, Oh DY, Kim DW, Kim TY, Heo DS, Bang YJ, Kim NK, Kang WK, Kim HT, Im SA, Suh JH, Kim HK, Kim HK. Park SR, et al. Among authors: kim dw, kim hk, kim ty, kim ht, kim nk. Oncol Rep. 2004 Nov;12(5):1059-64. Oncol Rep. 2004. PMID: 15492793 Clinical Trial.

2

Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: a Korean Cancer Study Group trial.

Kim TW, Kang WK, Chang HM, Park JO, Ryoo BY, Ahn JS, Zang DY, Lee KH, Kang YK, Kim SR, Kim HK; Korean Cancer Study Group. Kim TW, et al. Among authors: kim sr, kim hk. Acta Oncol. 2005;44(3):230-5. doi: 10.1080/02841860510029590. Acta Oncol. 2005. PMID: 16076694 Clinical Trial.

3

Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas.

Lee J, Kim TY, Lee MA, Ahn MJ, Kim HK, Lim HY, Lee NS, Park BJ, Kim JS; Korean Cancer Study Group. Lee J, et al. Among authors: kim hk, kim ty, kim js. Cancer Chemother Pharmacol. 2008 Jan;61(1):47-52. doi: 10.1007/s00280-007-0444-5. Epub 2007 Mar 16. Cancer Chemother Pharmacol. 2008. PMID: 17364190 Clinical Trial.

4

Multi-institutional phase II study of S-1 monotherapy in advanced gastric cancer with pharmacokinetic and pharmacogenomic evaluations.

Jeung HC, Rha SY, Kim HK, Lim HY, Kim S, Kim SY, Gong SJ, Park CH, Ahn JB, Noh SH, Chung HC. Jeung HC, et al. Among authors: kim hk, kim s, kim sy. Oncologist. 2007 May;12(5):543-54. doi: 10.1634/theoncologist.12-5-543. Oncologist. 2007. PMID: 17522242 Free article. Clinical Trial.

5

Phase I dose escalation study of docetaxel with a fixed dose of S-1 in combination chemotherapy for advanced gastric cancer.

Kim YH, Seo HY, Jeen YT, Kim HK, Shim BY, Yang J. Kim YH, et al. Among authors: kim hk. Cancer Chemother Pharmacol. 2009 Jan;63(2):253-60. doi: 10.1007/s00280-008-0734-6. Epub 2008 May 21. Cancer Chemother Pharmacol. 2009. PMID: 18493761 Clinical Trial.

6

Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study.

Lee KH, Kim MK, Kim YH, Ryoo BY, Lim HY, Song HS, Kim HK, Lee MA, Im SA, Chang HM, Cho JY, Zang DY, Kim BS, Kim JS. Lee KH, et al. Among authors: kim yh, kim bs, kim hk, kim js, kim mk. Cancer Chemother Pharmacol. 2009 Jul;64(2):317-25. doi: 10.1007/s00280-008-0873-9. Epub 2008 Nov 26. Cancer Chemother Pharmacol. 2009. PMID: 19034448 Clinical Trial.

7

Adenocarcinoma has an excellent outcome with pemetrexed treatment in Korean patients: a prospective, multicenter trial.

Lee HY, Ahn MJ, Park YH, Ahn JS, Kim BS, Kim HK, Kim HT, Ryoo HM, Bae SH, Lee SS, Choi K, Hong DS, Lee KH, Kwon JH, Choi IS, Kim BS, Lee NS, Gong SJ, Park K. Lee HY, et al. Among authors: kim bs, kim hk, kim ht. Lung Cancer. 2009 Dec;66(3):338-43. doi: 10.1016/j.lungcan.2009.02.008. Epub 2009 Mar 18. Lung Cancer. 2009. PMID: 19299031 Clinical Trial.

8

A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations.

Kim DW, Lee SH, Lee JS, Lee MA, Kang JH, Kim SY, Shin SW, Kim HK, Heo DS. Kim DW, et al. Among authors: kim hk, kim sy. Lung Cancer. 2011 Jan;71(1):65-9. doi: 10.1016/j.lungcan.2010.04.005. Lung Cancer. 2011. PMID: 20430469 Clinical Trial.

9

Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial.

Sun JM, Lee KH, Kim SW, Lee DH, Min YJ, Yun HJ, Kim HK, Song HS, Kim YH, Kim BS, Hwang IG, Lee K, Jo SJ, Lee JW, Ahn JS, Park K, Ahn MJ; Korean Cancer Study Group. Sun JM, et al. Among authors: kim yh, kim bs, kim hk, kim sw. Cancer. 2012 Dec 15;118(24):6234-42. doi: 10.1002/cncr.27630. Epub 2012 Jun 6. Cancer. 2012. PMID: 22674612 Free article. Clinical Trial.

10

A trial of autologous ex vivo-expanded NK cell-enriched lymphocytes with docetaxel in patients with advanced non-small cell lung cancer as second- or third-line treatment: phase IIa study.

Yang YJ, Park JC, Kim HK, Kang JH, Park SY. Yang YJ, et al. Among authors: kim hk. Anticancer Res. 2013 May;33(5):2115-22. Anticancer Res. 2013. PMID: 23645763 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

5,947 results

Search Page